

Certificate of Analysis

Wee1, active

(Recombinant enzyme expressed in Sf21 insect cells)

Item # 14-925, 14-925-K, 14-925M

Parent Lot # D12KP010N

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

Product Description: N-terminal GST-tagged and C-terminal 6His tagged, recombinant, human Wee1 amino acids 214-end expressed by baculovirus in Sf21 insect cells. Purified using glutathione agarose.

Purity 86.3% by SDS-PAGE and Coomassie blue staining. MW = 77kDa.

Specific Activity (Parent lot# D12KP010N): 101U/mg, where one unit of Wee1, active activity is defined as 1nmol phosphate incorporated into 500μM (LSNLYHQGKFLQTFCGSPLYRRR) per minute at 30°C with a final ATP concentration of 100μM.

Formulation: 0.23mg/ml of enzyme in 50mM Tris/HCl pH7.5, 300mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1% 2-mercaptoethanol. Frozen solution.


Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.


**FOR IN VITRO RESEARCH USE ONLY
NOT FOR USE IN HUMANS OR ANIMALS**

Quality Control Testing

Kinase Assay: 14–176ng of this lot of enzyme phosphorylated 500μM (LSNLYHQGKFLQTFCGSPLYRRR) in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



MS Tryptic Fingerprint: Confirmed identity as Wee1 with the translated sequence listed on page three.



SDS-PAGE and Coomassie Stain: Purity was assessed by SDS-PAGE and Coomassie blue staining using 3μg of Wee1, active.

Certificate of Analysis

Kinase Assay Protocol

Stock Solutions:

1. **5 x Reaction Buffer:** 100mM Tris/HCl pH8.5, 1mM EDTA.
2. **LSNLYHQGKFLQTFGSPLYRRR:** Use at a final assay concentration of 500 μ M. Prepare a 5mM stock and add 2.5 μ l of stock per assay point.
3. **Wee1, active:** Dilute with 20mM Tris/HCl pH8.5, 0.2mM EDTA, 0.01% Brij-35, 5% glycerol, 0.1% 2-mercaptoethanol. Use 14–176ng per assay point.
4. **[γ -³³P]ATP:** 2.5 x MgAc/[γ -³³P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [γ -³³P]ATP (specific activity approximately 500 - 800cpm/pmol as required).

Assay Procedure (96 well plate format):

1. Add 5 μ l of 5 x reaction buffer per assay to wells.
2. Add 2.5 μ l of (**LSNLYHQGKFLQTFGSPLYRRR**).
3. Add **2.5 μ l (14–176ng) Wee1, active**.
4. Add 5 μ l of dH₂O.
5. Add 10 μ l of diluted [γ -³³P]ATP mixture.
6. Incubate for 10 minutes at 30°C.
7. Stop the reaction by adding 5 μ l of 3% phosphoric acid.
8. Transfer a 10 μ l aliquot onto the appropriate area of a **P30 Filtermat**.
9. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
10. Wash the filtermat once for 2 minutes with methanol.
11. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
12. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1 μ l of 30% phosphoric acid.

Certificate of Analysis

Wee1 Sequence Information

<u>Protein</u>	human Wee1
<u>Tags</u>	N-terminal GST and C-terminal 6His
<u>Native sequence</u>	F230 of the recombinant protein is equivalent to F214 of human Wee1
<u>Accession number</u>	GenBank NM_003390

Recombinant Wee1 amino acid sequence:

```

1  MSPILGYWKI KGLVQPTRLL LEYLEEKYEE HLYERDEGDK WRNKKFELGL EFPNLPYYID
61  GDVKLTQSMa IIRYIADKHN MLGGCPKERA EISMLEGAVL DIRYGVSRIA YSKDFETLKV
121 DFLSKLPEML KMFEDRLCHK TYLNGDHVTH PDFMLYDALD VVLYMDPMCL DAFPKLVCFK
181 KRIEAIQID KYLKSSKYIA WPLQGWQATF GGGDHPPKSD LEVLFQGPEF MDTEKSGKRE
241 FDVRQTPQVN INPFTPDSLL LHSSGQCRRR KRTYWNDSCG EDMEASDYEL EDETRPAKRI
301 TITESNMKSR YTTEFHELEK IGSGEFGSVF KCVKRLDGC IYAIKRSKKPL AGSVDEQNAL
361 REVYAHAVLG QHSHVVRYFS AWAEDDHMLI QNEYCNGGSL ADAISENYRI MSYFKEAELK
421 DLLLQVGRGL RYIHSM SLVH MDIKPSNIFI SRTSIPNAAS EEGDEDDWAS NKVMFKIGDL
481 GHVTRISSPQ VEEGDSRFLA NEVLQENYTH LPKADIFALA LTVVCAAGAE PLPRNGDQWH
541 EIRQGRLPRI PQVLSQEFTE LLKVMIHDPD ERRPSAMALV KHSVLLSASR KSAEQLRIEL
601 NAEKFKNLL QKELKKAQMA KAAAEERALF TDRMATRSTT QSNRTSRLIG KKMNRSVSLT
661 IYHHHHHHH

```

Recombinant Wee1 nucleotide sequence:

```

1  atgtccccta tactaggtta ttggaaaatt aagggccttg tgcaaccac tgcacttctt
61  ttggaatatt ttgaagaaaa atatgaagag catttgatga agcgcatga aggtgataaa
121 tggcgaaaca aaaagtttga attgggtttg gagtttccca atcttcttta ttatatattgat
181 ggtgatgtta aattaacaca gtctatggcc atcatacggtt atatagctga caagcacaac
241 atgttgggtg gttgtccaaa agagcgtgca gagatttcaa tgcttgaagg agcgggtttg
301 gatattagat acggtgtttc gagaattgca tatagtaaag actttgaaac tctcaaaagt
361 gattttctta gcaagctacc tgaaatgctg aaaatgttcg aagatcggtt atgtcataaa
421 acatatattaa atggtgatca tgtaacccat cctgacttca tgttgatga cgctcttgat
481 gttgttttat acatggaccc aatgtgcctg gatgcgttcc caaaattagt ttgttttaaa
541 aaacgtattg aagctatccc acaaatgtat aagtacttga aatccagcaa gtatatagca
601 tggcctttgc agggctggca agccacgttt ggtggtggcg accatcctcc aaaatcggat
661 ctggaagtgc tgttccaggg gcccgaaattc atggatacag aaaaatcagg aaaaagggaa
721 ttgatgtgc gacagactcc tcaagtgaat attaatcctt ttactccgga ttctttgttg
781 cttcattcct caggacagtg tcgtcgtaga aagagaacgt attggaatga ttctcttggt
841 gaagacatgg aagccagtga ttatgagctt gaagatgaaa caagacctgc taagagaatt
901 acaattactg aaagcaatat gaagtcccg tatacaacag aatttcatga gctagagaaa
961 atcggctctg gagaatttgg ttctgtattt aagtgtgtga agaggctgga tggatgcatt
1021 tatgccatta agcgatcaaa aaagccattg gcgggctctg ttgatgagca gaacgctttg
1081 agagaagtat atgctcatgc agtgcttggc cagcattccc atgtagttcg atatttctct
1141 gcgtgggcag aagatgatca tatgcttata cagaatgaat attgtaatgg tggaaagttt
1201 gctgatgcta taagtgaata ctacagaatc atgagttact ttaaagaagc agagtgaag
1261 gatctctctt tgcaagttgg ccgaggcttg aggtatatcc attcaatgtc tttggttcac
1321 atggatataa aacctagtaa tattttcata tctcgaacct caatcccaaa tgctgcctct
1381 gaagaaggag acgaagatga ttgggcatcc aacaaagtta tgtttaaaat aggtgatctt
1441 gggcatgtaa caaggatctc cagtccacaa gttgaggagg gcgatagtcg ttttcttgca

```

Certificate of Analysis

```
1501 aatgaagttt tacaggagaa ttatacccat ctaccaaag cagatatttt tgcgcttgcc
1561 ctcacagtgg tatgtgctgc tgggtgctgaa cctcttccga gaaatggaga tcaatggcat
1621 gaaatcagac agggtagatt acctcgata ccacaagtgc tttccaaga atttacagag
1681 ttgctaaaag ttatgattca tccagatcca gagagaagac cttcagcaat ggcaactgga
1741 aagcattcag tattgctgtc cgcttctaga aagagtgcag aacaattacg aatagaattg
1801 aatgccgaaa agttcaaaaa ttacttttta caaaaagaac tcaagaaagc acagatggca
1861 aaagctgcag ctgaggaaaag agcactcttc actgaccgga tggccactag gtccaccacc
1921 cagagtaata gaacatctcg acttattgga aagaaaatga accgctctgt cagccttact
1981 atataccatc accatcacca tcactaa
```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services